Academia Sinica yesterday approved the resignation of distinguished research fellow Chen Ching-shih (陳慶士) after news of research misconduct in eight of his published papers was made public by the Ohio State University, where he previously served as a cancer researcher.
Academia Sinica said in a statement that it is sorry to hear about the incident, but added that Chen’s misconduct occurred before he became head of Academia Sinica’s Institute of Biological Chemistry in August 2014.
The institution’s Research Ethics Committee would still look into work he performed while serving at the academy, the statement added.
Chen’s resignation from the Academia Sinica comes after academic journal Science and the university issued separate reports on Friday regarding the findings of research misconduct that led to his resignation as a cancer researcher from the university last year.
The reports said the investigation found Chen had “intentionally committed research misconduct” in 14 instances in eight journal articles, and was guilty of “deviating from the accepted practices of image handling and figure generation and intentionally falsifying data.”
Chen admitted to the charges and resigned in September last year, the university said.
The university said it has requested an “immediate retraction” of the papers, published between 2006 and 2014, that contain the fabricated data.
However, the implications of the misconduct go beyond unreliable academic papers, as Chen’s work had raised millions of US dollars in funding and led to multiple patents and the establishment of two compounds in clinical trials.
The university said it immediately shut down a clinical trial of one of Chen’s anti-cancer agents that Arno Therapeutics Inc had been conducting after obtaining exclusive rights to test the agents.
A spokesperson for the company said that issues with Chen’s papers had “zero impact” on its drug development efforts, Science said.
The university said it “hired an external consultant who validated that Chen’s research misconduct did not affect the Arno licensed compounds developed in his lab.”
“Patient safety was never compromised,” the university’s statement said.
The university said it has forwarded the investigation to federal authorities, meaning Chen could continue to be investigated for his actions.
Academia Sinica first became aware of the matter about a year ago, but it had limited access to Chen’s questionable articles because the university did not reveal its investigation on its Web site until Friday, Academia Sinica Central Academic Advisory Committee executive secretary Henry Sun (孫以瀚) said yesterday.
This is the worst punishment a Taiwanese academic has ever received from a foreign institution, dealing a heavy blow to the nation’s image in international academia, Sun said.
Sun quoted Chen as saying that his laboratory staff “beautified” data to make their research look better, and that he was responsible for lax supervision.
Yesterday morning, Chen’s profile was accessible on the Institute of Biological Chemistry’s Web site, but it was later taken down after Chen tendered his verbal resignation to Academia Sinica president James Liao (廖俊智).
Meanwhile, China Medical University, where Chen in February temporarily served as the director of its Institute of New Drug Development, yesterday said it is unclear about the matter and is collecting information about the case.
Before Chen returned to Taiwan to serve as director of the Institute of Biological Chemistry in August 2014 — a position he held until August last year — he had taught at the Ohio State University’s College of Pharmacy, the University of Rhode Island and the University of Kentucky.
Specializing in medicinal chemistry, cancer studies, biological chemistry and translational medicine, Chen has received research awards from the US Prostate Cancer Foundation and the Hearst Foundation, and is a fellow at the American Association for the Advancement of Science.
In April last year, he and National Cheng Kung University researchers found a relation between vitamin E and cancer prevention, and created an anti-tumor agent that is 20 times more efficient than previous ones, which was then considered a potential opportunity to develop a new anti-cancer drug.
CROSS-STRAIT COLLABORATION: The new KMT chairwoman expressed interest in meeting the Chinese president from the start, but she’ll have to pay to get in Beijing allegedly agreed to let Chinese Nationalist Party (KMT) Chairwoman Cheng Li-wun (鄭麗文) meet with Chinese President Xi Jinping (習近平) around the Lunar New Year holiday next year on three conditions, including that the KMT block Taiwan’s arms purchases, a source said yesterday. Cheng has expressed interest in meeting Xi since she won the KMT’s chairmanship election in October. A source, speaking on condition of anonymity, said a consensus on a meeting was allegedly reached after two KMT vice chairmen visited China’s Taiwan Affairs Office Director Song Tao (宋濤) in China last month. Beijing allegedly gave the KMT three conditions it had to
STAYING ALERT: China this week deployed its largest maritime show of force to date in the region, prompting concern in Taipei and Tokyo, which Beijing has brushed off Deterring conflict over Taiwan is a priority, the White House said in its National Security Strategy published yesterday, which also called on Japan and South Korea to increase their defense spending to help protect the first island chain. Taiwan is strategically positioned between Northeast and Southeast Asia, and provides direct access to the second island chain, with one-third of global shipping passing through the South China Sea, the report said. Given the implications for the US economy, along with Taiwan’s dominance in semiconductors, “deterring a conflict over Taiwan, ideally by preserving military overmatch, is a priority,” it said. However, the strategy also reiterated
‘BALANCE OF POWER’: Hegseth said that the US did not want to ‘strangle’ China, but to ensure that none of Washington’s allies would be vulnerable to military aggression Washington has no intention of changing the “status quo” in the Taiwan Strait, US Secretary of Defense Pete Hegseth said on Saturday, adding that one of the US military’s main priorities is to deter China “through strength, not through confrontation.” Speaking at the annual Reagan National Defense Forum in Simi Valley, California, Hegseth outlined the US Department of Defense’s priorities under US President Donald Trump. “First, defending the US homeland and our hemisphere. Second, deterring China through strength, not confrontation. Third, increased burden sharing for us, allies and partners. And fourth, supercharging the US defense industrial base,” he said. US-China relations under
The Chien Feng IV (勁蜂, Mighty Hornet) loitering munition is on track to enter flight tests next month in connection with potential adoption by Taiwanese and US armed forces, a government source said yesterday. The kamikaze drone, which boasts a range of 1,000km, debuted at the Taipei Aerospace and Defense Technology Exhibition in September, the official said on condition of anonymity. The Chungshan Institute of Science and Technology and US-based Kratos Defense jointly developed the platform by leveraging the engine and airframe of the latter’s MQM-178 Firejet target drone, they said. The uncrewed aerial vehicle is designed to utilize an artificial intelligence computer
RSS